Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light.

Published byTomas Austad Modified over 5 years ago

Similar presentations

Presentation on theme: "Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light."— Presentation transcript:

1 Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light red), and in patients with chronic obstructive pulmonary disease (COPD) in Medicare (dark cyan) and in C... Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light red), and in patients with chronic obstructive pulmonary disease (COPD) in Medicare (dark cyan) and in CHSS (dark red). The comparative analysis within datasets shows that the prevalence of most of the DGs is higher in patients with COPD (dark colour) than in the entire population (light colour). Differences in the prevalence between datasets are fully explainable by methodological heterogeneities, detailed in the main text. Healthcare system-related differences in comorbidity associations were compared using two-sided t-tests of relative risk measures (*), p< Ákos Tényi et al. BMJ Open Resp Res 2018;5:e000302 ©2018 by British Thoracic Society

Download ppt "Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light."

Similar presentations

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. ABG,

Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. ABG,
Flow diagram of participants included in the survey. aResponse rate

Flow diagram of participants included in the survey. aResponse rate
The significantly different metabolites between the systemic inflammatory response syndrome SIRS (n=15) and sepsis (n=35) groups (A); the sepsis (n=10)

The significantly different metabolites between the systemic inflammatory response syndrome SIRS (n=15) and sepsis (n=35) groups (A); the sepsis (n=10)
Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Image of the form used by ambulance officers to triage patients with an exacerbation of chronic obstructive pulmonary disease (COPD).  GP, general practitioner;

Image of the form used by ambulance officers to triage patients with an exacerbation of chronic obstructive pulmonary disease (COPD).  GP, general practitioner;
Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.

Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.
Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.
Monthly admissions for chronic obstructive pulmonary disease (COPD) to Christchurch Hospital. Monthly admissions for chronic obstructive pulmonary disease.

Monthly admissions for chronic obstructive pulmonary disease (COPD) to Christchurch Hospital. Monthly admissions for chronic obstructive pulmonary disease.
The top 25 analytes by relevant q-value differentially expressed in HIV with COPD. The top number is m/z and the bottom number is RT. Y-axis is intensity.

The top 25 analytes by relevant q-value differentially expressed in HIV with COPD. The top number is m/z and the bottom number is RT. Y-axis is intensity.
For most patients with asthma airway response becomes flatter after 1000 µg of inhaled corticosteroid, but systemic activity (measured by serum cortisol.

For most patients with asthma airway response becomes flatter after 1000 µg of inhaled corticosteroid, but systemic activity (measured by serum cortisol.
Serum levels of angiopoietin-like protein 4 (ANGPTL4) according to patients with chronic obstructive pulmonary disease and controls without any lung disease.

Serum levels of angiopoietin-like protein 4 (ANGPTL4) according to patients with chronic obstructive pulmonary disease and controls without any lung disease.
Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.

Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.
A white elephant or the elephant in the room

A white elephant or the elephant in the room
(A, B) Airway circularity (Cr), (C, D) normalised wall thickness (WT

(A, B) Airway circularity (Cr), (C, D) normalised wall thickness (WT
Comparison of the age-associated prevalence (y axis) in the Catalan Healthcare Surveillance System (CHSS) and Medicare datasets of selected disease groups.

Comparison of the age-associated prevalence (y axis) in the Catalan Healthcare Surveillance System (CHSS) and Medicare datasets of selected disease groups.
Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.

Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.

Similar presentations

Ads by Google